Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lercanidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lercanidipine SCHEMBL29541187 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL31429659 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL30158506 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25269 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL1819021 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25268 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8415026 | 1.00 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL4730008 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8630225 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL29349606 | 0.99 | ADORA3 (0.98) | ADORA3ADRA1AMTORRAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654729-A2 | HOMOGENOUS PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING LERCANIDIPINE AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | KRKA, d.d., Novo mesto (SI) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085249-A2 | HOMOGENOUS PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING LERCANIDIPINE AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | KRKA, D.D., NOVO MESTO (SI) | 2012-06-28 | — | — | WO | disclosed |